AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

A storm is brewing in U.S.–Mexico relations, and its epicenter is the newly appointed U.S. ambassador: Ronald Johnson, a ...

In their upside down, Alice-in-Wonderland version of reality, the left has a point when they cast George Orwell as a prophet ...

Institutional autonomy Universities must be able to operate independently, free from imposed political, ideological, or commercial influence. Institutional autonomy is not a privilege, but a necessary ...

Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in modera ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, has reported its ...